Fibromyalgia Syndrome: A Discussion of the Syndrome and Pharmacotherapy

Disease-a-Month

Volumn 57, Issue 5, 2011, Pages 248-285

  Smith, Howard S ^a   Barkin, Robert L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLORGYLINE; CYCLOBENZAPRINE; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FURAZOLIDONE; GABAPENTIN; IPRONIAZID; ISOCARBOXAZID; MILNACIPRAN; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NIALAMIDE; NORTRIPTYLINE; PARGYLINE; PHENELZINE; PREGABALIN; PROCARBAZINE; RASAGILINE; SELEGILINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

AEROBIC EXERCISE; ANGIONEUROTIC EDEMA; ANOREXIA; ANOREXIA NERVOSA; ANXIETY; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; ASTHENIA; ATAXIA; ATTENTION DISTURBANCE; BLEEDING DISORDER; BLURRED VISION; COGNITIVE DEFECT; COGNITIVE THERAPY; CONFUSION; CONSTIPATION; DECREASED APPETITE; DEPRESSION; DIABETIC NEUROPATHY; DIAPHORESIS; DIARRHEA; DIZZINESS; DROWSINESS; DYSPEPSIA; ECCHYMOSIS; EDEMA; EUPHORIA; FATIGUE; FIBROMYALGIA; GENERALIZED ANXIETY DISORDER; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEART PALPITATION; HUMAN; HYPERALGESIA; HYPERHIDROSIS; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERURICOSURIA; HYPOMANIA; HYPONATREMIA; HYPOTENSION; INAPPROPRIATE VASOPRESSIN SECRETION; INSOMNIA; INTERSTITIAL CYSTITIS; IRRITABILITY; IRRITABLE COLON; LIBIDO DISORDER; LIVER DISEASE; MANIA; MENTAL DISEASE; MUSCULOSKELETAL PAIN; MYDRIASIS; NAUSEA; NERVOUSNESS; NEUROMUSCULAR DISEASE; NIGHTMARE; NOCICEPTION; ORTHOSTATIC HYPOTENSION; PAIN; PARESTHESIA; PATHOPHYSIOLOGY; PATIENT EDUCATION; PERIPHERAL EDEMA; PHOTOSENSITIVITY; POSTHERPETIC NEURALGIA; PRURITUS; QT PROLONGATION; RASH; RHABDOMYOLYSIS; RIGIDITY; SEIZURE; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SINUS TACHYCARDIA; SLEEP DISORDER; SOMNOLENCE; STROKE; SUICIDAL BEHAVIOR; SYNCOPE; TACHYCARDIA; TEMPOROMANDIBULAR JOINT DISORDER; THROMBOCYTOPENIA; TREMOR; URTICARIA; VOMITING; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANALGESICS; ANALGESICS, OPIOID; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COGNITIVE THERAPY; DRUG MONITORING; DRUG THERAPY, COMBINATION; EXERCISE; FIBROMYALGIA; HUMANS; META-ANALYSIS AS TOPIC; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SYNDROME; TREATMENT OUTCOME;

EID: 79957651980     PISSN: 00115029     EISSN: 15578194     Source Type: Journal    
DOI: 10.1016/j.disamonth.2011.02.001     Document Type: Article

References (110)

1. Wolfe F., Ross K., Anderson J., et al. The prevalence and characteristics of fibromylagia in the general population. Arthritis Rheum 1995, 38:19-28.
2. Miedema H.S., van der Linden S.M., Rasker J.J., et al. National database of patients visiting rheumatologists in The Netherlands: the standard diagnosis register of rheumatic diseases. A report and preliminary analysis. Br J Rheumatol 1998, 37:555-561.
3. Buskila D., Sarzi-Puttini P. Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome. Arthritis Res Ther 2006, 8:218.
4. Arnold L.M., Hudson J.L., Hess E.V., et al. Family study of fibromyalgia. Arthritis Rheum 2004, 50:944-952.
5. Cohen H., Buskila D., Neumann L., et al. Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5-HTTLPR) polymorphism, and relationship to anxiety related personality traits. Arthritis Rheum 2002, 46:845-847.
6. Gursoy S. Absence of association of the serotonin transporter gene polymorphism with the mentally healthy subset of fibromyalgia patients. Clin Rheumatol 2002, 21:194-197.
7. Gursoy S., Erdal E., Herken H., et al. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int 2003, 23:104-107.
8. Buskila D., Cohen H., Neumann L., et al. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship personality traits. Mol Psychiatry 2004, 9:730-731.
9. Bennett R.M., Jones J., Turk D.C., et al. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord 2007, 8:27.
10. Jones J., Rutledge D.N., Jones K.D., et al. Self-assessed physical function levels of women with fibromyalgia: a national survey. Womens Health Issues 2008, 18:406-412.
11. Carmona L., Ballina J., Gabriel R., et al. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis 2001, 60:1040-1045.
12. Bernard A.L., Prince A., Edsall P. Quality of life issues for fibromyalgia patients. Arthritis Care Res 2000, 13:42-50.
13. Burckhardt C.S., Clark S.R., Bennett R.M. Fibromyalgia and quality of life: a comparative analysis. J Rheumatol 1993, 20:475-479.
14. Wolfe F., Smythe H.A., Yunus M.B., et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33:160-172.
15. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl 2005, 75:6-21.
16. Orellana C., Casado E., Masip M., et al. Sexual dysfunction in fibromyalgia patients. Clin Exp Rheumatol 2008, 26:663-666.
17. Kalichman L. Association between fibromyalgia and sexual dysfunction in women. Clin Rheumatol 2009, 28:365-369.
18. Staud R. Fibromyalgia syndrome. Current Therapy in Pain 2009, 233-240. Elsevier, Philadelphia. H.S. Smith (Ed.).
19. McCarberg B., Barkin R.L., Wright J.A., et al. Tender points as predictors of distress and the pharmacologic management of fibromyalgia syndrome. Am J Ther 2003, 10:176-192.
20. Wolfe F., Clauw D.J., Fitzcharles M.A., et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010, 62:600-610.
21. Wolfe F, Clauw D, Fitzcharles MA, et al. Clinical Diagnostic and Severity Criteria for Fibromyalgia. Presentation 567. ACR/ARHP Scientic Meeting; Philadelphia, PA; October 18, 2009.
22. Prins M.A., Woertman L., Kool M.B., et al. Sexual functioning of women with fibromyalgia. Clin Exp Rheumatol 2006, 24:555-561.
23. Shaver J.L., Wilbur J., Robinson F.P., et al. Women's health issues with fibromyalgia syndrome. J Women's Health (Larchmt) 2006, 15:1035-1045.
24. Rosenbaum T.Y. Musculoskeletal pain and sexual function in women. J Sex Med 2010, 7:645-653.
25. Orellana C., Grataco's J., Galisteo C., et al. Sexual dysfunction in patients with fibromyalgia. Curr Rheumatol Rep 2009, 11:437-442.
26. Vaerøy H., Helle R., Førre O., et al. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988, 32:21-26.
27. Russell I.J., Orr M.D., Littman B., et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994, 37:1593-1601.
28. Liu Z., Welin M., Bragee B., et al. A high-recovery extraction procedure for quantitative analysis of substance P and opioid peptides in human cerebrospinal fluid. Peptides 2000, 21:853-860.
29. Bradley L.A., Alarco'm G.S. Is Chiari malformation associated with increased levels of substance P and clinical symptoms in persons with fibromyalgia?. Arthritis Rheum 1999, 42:2731-2732.
30. Russell I.J., Vaerøy H., Javors M., et al. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992, 35:550-556.
31. Sarchielli P., Mancini M.L., Floridi A., et al. Increased levels of neurotrophins are not specific for chronic migraine: evidence from primary fibromyalgia syndrome. J Pain 2007, 8:737-745.
32. Bennett R.M., Friend R., Jones K.D., et al. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther 2009, 11:R120.
33. Haüser W., Bernardy K., Ucxeyler N., et al. Treatment of fibromyalgia syndrome with antidepressants: a metaanalysis. JAMA 2009, 301:198-209.
34. Hansten P.D., Horn J.R. The Top 100 Drug Interactions-A Guide to Patient Management 2010, H&H Publications, LLP, Freeland, WA.
35. Wickersham R.M. Senior Managing editor, Drug Facts and comparisons. E-answers 2010 Wolter Kluwer Health, Inc., Accessed May 25, 2010. http://www.factsandcomparisons.com/facts-comparison-online.aspx.
36. Arnold L.M. Duloxetine and other antidepressants in the treatment of patients with fibromyalgia. Pain Med 2007, 8:S63-S74.
37. Beebe F.A., Barkin R.L., Barkin S. A clinical and pharmacologic review of skeletal muscle relaxants for musculoskeletal conditions. Am J Ther 2005, 12:151-171.
38. Brown D.V., Heller F., Barkin R. Anticholinergic syndrome after anesthesia: a case report and review. Am J Ther 2004, 11:144-153.
39. Barkin R.L. Extended-release tramadol (ULTRAM ER): a pharmacotherapeutic, pharmacokinetic, and pharmacodynamic focus on effectiveness and safety in patients with chronic/persistent pain. Am J Ther 2008, 15:157-166.
40. Barkin R.L. Duloxetine: A pharmacological overview. Pain Medicine Network 2007, 22:8-11.
41. Arnold L.M., Lu Y., Crofford L.J., et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004, 50:2974-2984.
42. Arnold L.M., Rosen A., Pritchett Y.L., et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005, 119:5-15.
43. Russell I.J., Mease P.J., Smith T.R., et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008, 136:432-444.
44. Chappell A.S., Bradley L.A., Wiltse C., et al. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med 2008, 1:91-102.
45. Arnold L.M., Clauw D.J., Wohlreich M.M., et al. Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials. Prim Care Companion J Clin Psychiatry 2009, 11:237-244.
46. Barkin R.L. Milnacipran: a pharmacotherapeutic-focused brief review. Pain Medicine Network 2009, 23:8-9.
47. Vitton O., Gendreau M., Gendreau J., et al. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004, 19:S27-S35.
48. Clauw D.J., Mease P., Palmer R.H., et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008, 30:1988-2004.
49. Mease P.J., Clauw D.J., Gemdreau R.M., et al. The efficacy and safety of milnacipran for treatment of fibromyalgia, a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009, 36:398-409.
50. Goldenberg D.L., Clauw D.J., Palmer R.H., et al. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Med 2010, 11:180-194.
51. Chwieduk C.M., McCormack P.L. Milnacipran: in fibromyalgia. Drugs 2010, 70:99-108.
52. Mease P., Palmer R.H., Wang Y., et al. Milnacipran improves fatigue in fibromyalgia: pooled analyses from 3 randomized, placebo-controlled clinical Trials [Abstract]. Arthritis Rheum 2009, 60:1423.
53. Taylor C.P., Angelotti T., Fauman E. Pharmacology and mechanism of action of pregabalin: The calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Research 2007, 73:137-150.
54. Barkin R.L. Pregabalin: a critical review. Pain Medicine Network 2008, 24:8-9.
55. Blommel M.L., Blommel A.L. Pregabalin: an antiepileptic agent useful for neuropathic pain. American Journal of Health-System Pharmacy 2007, 64:1475-1482.
56. Barkin R.L. Methadone: a novel and potentially hazardous opioid analgesic. Pain Medicine Network 2006, 21:4-11.
57. FDA Alert: Information for Healthcare Professionals Suicidality and Antiepileptic Drugs US Food and Drug Administration (2008, January 31), Accessed April 10, 2008. http://www.fda.gov/Cder/Drug/InfoSheets/HCP/antiepilepticsHCP.htm.
58. Crofford L.J., Rowbotham M.C., Mease P.J., et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo controlled trial. Arthritis Rheum 2005, 52:1264-1267.
59. Arnold L.M., Russell I.J., Diri E.W., et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008, 9:792-805.
60. Mease P.J., Russell I.J., Arnold L.M., et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008, 35:502-514.
61. Pauer L., Danneskiold-Samsoe B., Jespersen A., et al. Pregabalin for management of fibromyalgia (FM): a 14-week, randomized, double-blind, placebo-controlled monotherapy trial (study A0081100). Ann Rheum Dis 2008, 67:S256.
62. Haüser W., Bernardy K., Ucxeyler N., et al. Treatment of fibromyalgia syndrome with gabapentin and pregabalin-a meta-analysis of randomized controlled trials. Pain 2009, 145:69-81.
63. Barkin R.L. Tapentadol: a pharmacotherapeutic-focused brief review. Pain Medicine Network 2009, 24:8-11.
64. Kleinert R., Lange C., Steup A., et al. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study. Anesth Analg 2008, 107:2048-2055.
65. Daniels S.E., Upmalis D., Okamoto A., et al. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin 2009, 25:765-776.
66. Hale M., Upmalis D., Okamoto A., et al. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr Med Res Opin 2009, 25:1095-1104.
67. Etropolski M.S., Okamoto A., Shapiro D.Y., et al. Dose conversion between tapentadol immediate and extended release for low back pain. Pain Physician 2010, 13:61-70.
68. Sloan P.A., Barkin R.L. Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review. J Opioid Manage 2008, 14:145-152.
69. Barkin R.L. Drug metabolism. Pain Medicine Network 2007, 22:6-7.
70. Barkin R.L. Incorporation of science and clinical medicine in the process of patient-specific and patient-centered, patient focused prescribing and personalized patient care. Pain Medicine Network 2008, 23:4-9.
71. Katz N., Fanciullo G.J. Role of urine toxicology testing in the management of chronic opioid therapy. Clin J Pain 2002, 18:S76-S82.
72. Jones K.D., Liptan G.L. Exercise interventions in fibromyalgia: clinical applications from the evidence. Rheum Dis Clin N Am 2009, 35:373-391.
73. Alentorn-Geli E., Padilla J., Moras G., et al. Six weeks of whole-body vibration exercise improves pain and fatigue in women with fibromyalgia. J Altern Complement Med 2008, 14:975-981.
74. da Silva G.D., Lorenzi-Filho G., Lage L.V. Effects of yoga and the addition of Tui Na in patients with fibromyalgia. J Altern Complement Med 2007, 13:1107-1113.
75. de Andrade S.C., de Carvalho R.F., Soares A.S., et al. Thalassotherapy for fibromyalgia: a randomized controlled trial comparing aquatic exercises in sea water and water pool. Rheumatol Int 2008, 29:147-152.
76. Evcik D., Yigit I., Pusak H., et al. Effectiveness of aquatic therapy in the treatment of fibromyalgia syndrome: a randomized controlled open study. Rheumatol Int 2008, 28:885-890.
77. Figueroa A., Kingsley J.D., McMillan V., et al. Resistance exercise training improves heart rate variability in women with fibromyalgia. Clin Physiol Funct Imaging 2008, 28:49-54.
78. Fontaine K., Haaz S. Effects of lifestyle physical activity on health status, pain, and function in adults with fibromyalgia syndrome. J Muscoskel Pain 2007, 15:3-9.
79. Gusi N., Tomas-Carus P. Cost-utility of an 8-month aquatic training for women with fibromyalgia: a randomized controlled trial [Abstract]. Arthritis Res Ther 2008, 10:R24.
80. Haak T., Scott B. The effect of Qigong on fibromyalgia (FMS): a controlled randomized study. Disabil Rehabil 2008, 30:625-633.
81. Jones K.D., Burckhardt C.S., Deodhar A.A., et al. A six month randomized controlled trial of exercise and pyridostigmine in the treatment of fibromyalgia. Arthritis Rheum 2008, 58:612-622.
82. Kayo A., Sanches C., Montegro-Rodrigues R., et al. Effectiveness of physical exercise on decrease of pain in patients with fibromyalgia [Abstract]. Arthritis Rheum 2007, 56:532.
83. Mannerkorpi K., Nordeman L., Ericsson A., et al. Pool exercise produces therapeutic effects in patients with fibromyalgia or chronic widespread pain. J Rehabil Med 2009, 41:751-760.
84. Matsutani L.A., Marques A.P., Ferreira E.A., et al. Effectiveness of muscle stretching exercises with and without laser therapy at tender points for patients with fibromyalgia. Clin Exp Rheumatol 2007, 25:410-415.
85. Munguia-Izquierdo D., Legaz-Arrese A. Assessment of the effects of aquatic therapy on global symptomatology in patients with fibromyalgia syndrome: a randomized controlled trial. Arch Phys Med Rehabil 2008, 89:2250-2257.
86. Rooks D.S., Gautam S., Romeling M., et al. Group exercise, education, and combination self-management in women with fibromyalgia: a randomized trial. Arch Intern Med 2007, 167. 2192-1200.
87. Stephens S., Feldman B.M., Bradley N., et al. Feasibility and effectiveness of an aerobic exercise program in children with fibromyalgia: results of a randomized controlled pilot trial. Arthritis Rheum 2008, 59:1399-1406.
88. Tomas-Carus P., Hakkinen A., Gusi N., et al. Aquatic training and detraining on fitness and quality of life in fibromyalgia. Med Sci Sports Exerc 2007, 39:1044-1050.
89. Tomas-Carus P., Gusi N., Hakkinen A., et al. Eight months of physical training in warm water improves physical and mental health in women with fibromyalgia: a randomized controlled trial. J Rehabil Med 2008, 40:248-252.
90. Valkeinen H., Alen M., Hakkinen A., et al. Effects of concurrent strength and endurance training on physical fitness and symptoms in postmenopausal women with fibromyalgia: a randomized controlled trial. Arch Phys Med Rehabil 2008, 89:1660-1666.
91. van Santen M., Bolwijn P., Landewe R., et al. High or low intensity aerobic fitness training in fibromyalgia: does it matter?. J Rheumatol 2002, 29:582-587.
92. Jones K.D., Burckhardt C.S., Clark S.R., et al. A randomized controlled trial of muscle strengthening versus flexibility training in fibromyalgia. J Rheumatol 2002, 29:1041-1048.
93. Kingsley J.D., Panton L.B., Toole T., et al. The effects of a 12-week strength-training program on strength and functionality in women with fibromyalgia. Arch Phys Med Rehabil 2005, 86:1713-1721.
94. Bircan C., Karasel S.A., Akgun B., et al. Effects of muscle strengthening versus aerobic exercise program in fibromyalgia. Rheumatol Int 2008, 28:527-532.
95. Hakkinen K., Pakarinen A., Hannonen P., et al. Effects of strength training on muscle strength, cross-sectional area, maximal electromyographic activity, and serum hormones in premenopausal women with fibromyalgia. J Rheumatol 2002, 29:1287-1295.
96. Hannonen P., Rahkita P., Kallinen M., et al. Effects of prolonged vs muscle strengthen programs on fibromyalgia [Abstract]. J Muscoskel Pain 1995, 70:34.
97. Valkeinen H., Hakkinen K., Pakarinen A., et al. Muscle hypertrophy, strength development, and serum hormones during strength training in elderly women with fibromyalgia. Scand J Rheumatol 2005, 34:309-314.
98. Valkeinen H., Hakkinen A., Hannonen P., et al. Acute heavy-resistance exercise induced pain and neuromuscular fatigue in elderly women with fibromyalgia and in healthy controls: effects of strength training. Arthritis Rheum 2006, 54:1334-1349.
99. Martin L., Nutting A., MacIntosh B.R., et al. An exercise program in the treatment of fibromyalgia. J Rheumatol 1996, 23:1050-1053.
100. McCain G.A., Bell D.A., Mai F.M., et al. A controlled study of the effects of a supervised cardiovascular fitness training program on the manifestations of primary fibromyalgia. Arthritis Rheum 1988, 31:1135-1141.
101. Richards S.C., Scott D.L. Prescribed exercise in people with fibromyalgia: parallel group randomised controlled trial. BMJ 2002, 325:185.
102. Valim V., Oliveira L., Suda A., et al. Aerobic fitness effects in fibromyalgia. J Rheumatol 2003, 30:1060-1069.
103. Beck A.T. Thinking and depression: theory and therapy. Arch Gen Psychiatry 1964, 10:561-571.
104. Thieme K., Flor H., Turk D.C. Psychological pain treatment in fibromyalgia syndrome: efficacy of operant behavioural and cognitive behavioural treatments. Arthritis Res Ther 2006, 8:R121.
105. Va'zquez-Rivera S., Gonza'lez-Blanch C., Rodriguez-Moya L., et al. Brief cognitive-behavioral therapy with fibromyalgia patients in routine care. Compr Pstchiatry 2009, 50:517-525.
106. Williams D.A., Cary M.A., Groner K.H., et al. Improving physical functional status in patients with fibromyalgia: a brief cognitive behavioral intervention. J Rheumatol 2002, 29:1280-1286.
107. Allen L.A., Woolfolk R.L., Escobar J.I., et al. Cognitive- behavioral therapy for somatization disorder: a randomized controlled trial. Arch Intern Med 2006, 166:1512-1518.
108. Burckhardt C.S., Goldenberg D., Crofford L., et al. Guideline for the Management of Fibromyalgia Syndrome. Pain in Adults and Children 2005, APS Clinical Practice Guideline Series No 4, American Pain Society, Glenview, IL.
109. Carville S.F., Arendt-Nielsen S., Bliddal H., et al. EULAR evidence-based recommendations for the management of fibromylagia syndrome. Ann Rheum Dis 2008, 67:536-541.
110. Klement A., Haüser W., Brückle W., et al. General principles of therapy, coordination of medical care and patient education in fibromyalgia syndrome and chronic widespread pain [in German]. Schmerz 2008, 22:283-294.